Scott Kanner
Co-founder Stablix
Scott Kanner is co-inventor of the company’s foundational platform and heads the research and development of platform technologies at Stablix. As a training physician-scientist at the Medical Scientist Training Program (MSTP) at Columbia University’s Vagelos College of Physicians & Surgeons, Scott received his PhD in Neuroscience and the NIH National Research Service Award.
Seminars
Thursday 30th October 2025
Panel Discussion: Exploring the Frontier Beyond Traditional Degradation: Challenges, Opportunities & Emerging Modalities
9:15 am
- Defining key principles for expanding the druggable proteome and identifying targets amenable to novel induced proximity strategies
- Investigating unmet needs where emerging modalities outperform traditional degradation and uncovering new therapeutic niches
- Addressing translational hurdles for novel approaches and highlighting biotech priorities in overcoming delivery, specificity and scalability challenges
- Spotlighting the most exciting new directions in induced proximity, from novel E3 ligases to non-degradative functional modulation
Thursday 30th October 2025
Harnessing Targeted Protein Deubiquitination as a Novel Therapeutic Modality
11:30 am
- Overview of Stablix and targeted deubiquitination therapeutics
- Profiling novel ligands for DUB recruitment and bifunctional development
- Identifying therapeutically relevant proteins for targeted protein deubiquitination and stabilization
